256 related articles for article (PubMed ID: 30175971)
1. Aberrant NEAT1_1 expression may be a predictive marker of poor prognosis in diffuse large B cell lymphoma.
Deng L; Jiang L; Tseng KF; Liu Y; Zhang X; Dong R; Lu Z; Wang X
Cancer Biomark; 2018; 23(2):157-164. PubMed ID: 30175971
[TBL] [Abstract][Full Text] [Related]
2. Elevated RNA expression of long non‑coding HOTAIR promotes cell proliferation and predicts a poor prognosis in patients with diffuse large B cell lymphoma.
Yan Y; Han J; Li Z; Yang H; Sui Y; Wang M
Mol Med Rep; 2016 Jun; 13(6):5125-31. PubMed ID: 27122348
[TBL] [Abstract][Full Text] [Related]
3. LncRNA MALAT1 promotes tumorigenesis and immune escape of diffuse large B cell lymphoma by sponging miR-195.
Wang QM; Lian GY; Song Y; Huang YF; Gong Y
Life Sci; 2019 Aug; 231():116335. PubMed ID: 30898647
[TBL] [Abstract][Full Text] [Related]
4. LincRNA-p21 predicts favorable clinical outcome and impairs tumorigenesis in diffuse large B cell lymphoma patients treated with R-CHOP chemotherapy.
Peng W; Wu J; Feng J
Clin Exp Med; 2017 Feb; 17(1):1-8. PubMed ID: 26475621
[TBL] [Abstract][Full Text] [Related]
5. Increased expression of IRF8 in tumor cells inhibits the generation of Th17 cells and predicts unfavorable survival of diffuse large B cell lymphoma patients.
Zhong W; Xu X; Zhu Z; Du Q; Du H; Yang L; Ling Y; Xiong H; Li Q
Oncotarget; 2017 Jul; 8(30):49757-49772. PubMed ID: 28537908
[TBL] [Abstract][Full Text] [Related]
6. Long noncoding RNA HULC predicts poor clinical outcome and represents pro-oncogenic activity in diffuse large B-cell lymphoma.
Peng W; Wu J; Feng J
Biomed Pharmacother; 2016 Apr; 79():188-93. PubMed ID: 27044827
[TBL] [Abstract][Full Text] [Related]
7. LncRNA NEAT1 regulate diffuse large B-cell lymphoma by targeting miR-495-3p/PD-L1 axis.
Yuan J; Yang J; Wang R; Hao H; Li J
Immunopharmacol Immunotoxicol; 2022 Jun; 44(3):429-436. PubMed ID: 35352617
[TBL] [Abstract][Full Text] [Related]
8. [Impact of PRDM1 gene inactivation on C-MYC regulation in diffuse large B-cell lymphoma].
Zhang XY; Ma ZP; Cui WL; Pang XL; Chen R; Wang L; Zhang W; Li XX
Zhonghua Bing Li Xue Za Zhi; 2018 Jan; 47(1):25-31. PubMed ID: 29325247
[No Abstract] [Full Text] [Related]
9. Discovery and validation of immune-associated long non-coding RNA biomarkers associated with clinically molecular subtype and prognosis in diffuse large B cell lymphoma.
Zhou M; Zhao H; Xu W; Bao S; Cheng L; Sun J
Mol Cancer; 2017 Jan; 16(1):16. PubMed ID: 28103885
[TBL] [Abstract][Full Text] [Related]
10. Upregulation of long noncoding RNA PEG10 associates with poor prognosis in diffuse large B cell lymphoma with facilitating tumorigenicity.
Peng W; Fan H; Wu G; Wu J; Feng J
Clin Exp Med; 2016 May; 16(2):177-82. PubMed ID: 25864113
[TBL] [Abstract][Full Text] [Related]
11. Long noncoding RNA LUNAR1 associates with cell proliferation and predicts a poor prognosis in diffuse large B-cell lymphoma.
Peng W; Feng J
Biomed Pharmacother; 2016 Feb; 77():65-71. PubMed ID: 26796267
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic strategy with artificially-designed i-lncRNA targeting multiple oncogenic microRNAs exhibits effective antitumor activity in diffuse large B-cell lymphoma.
Su Y; Sun B; Lin X; Zhao X; Ji W; He M; Qian H; Song X; Yang J; Wang J; Chen J
Oncotarget; 2016 Aug; 7(31):49143-49155. PubMed ID: 27172795
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance and detection of microRNA-21 in serum of patients with diffuse large B-cell lymphoma in Chinese population.
Chen W; Wang H; Chen H; Liu S; Lu H; Kong D; Huang X; Kong Q; Lu Z
Eur J Haematol; 2014; 92(5):407-12. PubMed ID: 24400911
[TBL] [Abstract][Full Text] [Related]
14. Sirt6 promotes tumorigenesis and drug resistance of diffuse large B-cell lymphoma by mediating PI3K/Akt signaling.
Yang J; Li Y; Zhang Y; Fang X; Chen N; Zhou X; Wang X
J Exp Clin Cancer Res; 2020 Jul; 39(1):142. PubMed ID: 32711549
[TBL] [Abstract][Full Text] [Related]
15. PMA/IONO affects diffuse large B-cell lymphoma cell growth through upregulation of A20 expression.
Yang W; Li Y; Li P; Wang L
Oncol Rep; 2016 Aug; 36(2):1069-75. PubMed ID: 27349720
[TBL] [Abstract][Full Text] [Related]
16. Long non-coding RNA NEAT1 overexpression is associated with unfavorable prognosis in patients with hepatocellular carcinoma after hepatectomy: A Chinese population-based study.
Liu Z; Chang Q; Yang F; Liu B; Yao HW; Bai ZG; Pu CS; Ma XM; Yang Y; Wang TT; Guo W; Zhou XN; Zhang ZT
Eur J Surg Oncol; 2017 Sep; 43(9):1697-1703. PubMed ID: 28732670
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-9 promotes cell survival and drug resistance in diffuse large B-cell lymphoma.
Lv X; Feng L; Ge X; Lu K; Wang X
J Exp Clin Cancer Res; 2016 Jul; 35(1):106. PubMed ID: 27364124
[TBL] [Abstract][Full Text] [Related]
18. LncRNA, NEAT1 is a prognosis biomarker and regulates cancer progression via epithelial-mesenchymal transition in clear cell renal cell carcinoma.
Ning L; Li Z; Wei D; Chen H; Yang C
Cancer Biomark; 2017; 19(1):75-83. PubMed ID: 28269753
[TBL] [Abstract][Full Text] [Related]
19. [Expression of miR-126 in Diffuse Large B-Cell Lymphoma and Its Biological Function].
Qiu C; Zhang QH; Wang GG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1415-1422. PubMed ID: 36208243
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-23a expression in paraffin-embedded specimen correlates with overall survival of diffuse large B-cell lymphoma.
Wang WL; Yang C; Han XL; Wang R; Huang Y; Zi YM; Li JD
Med Oncol; 2014 Apr; 31(4):919. PubMed ID: 24659264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]